A novel nomogram for predicting HBeAg seroclearance in HBeAg-positive chronic hepatitis B patients treated with nucleos(t)ide analogues

被引:0
|
作者
Gu, Yan [1 ]
Zhang, Yao [1 ]
Zhang, Zhiyi [1 ]
Wang, Jian [2 ,3 ]
Zhang, Qing [4 ]
Zhang, Shaoqiu [2 ]
Liu, Yilin [1 ]
Liu, Jiacheng [2 ]
Xia, Juan [2 ]
Yan, Xiaomin [2 ]
Li, Jie [1 ,2 ,3 ]
Liu, Xingxiang [5 ]
Huang, Rui [1 ,2 ,3 ]
Wu, Chao [1 ,2 ,3 ]
机构
[1] Nanjing Univ Chinese Med, Nanjing Drum Tower Hosp, Clin Coll, Dept Infect Dis, Nanjing, Jiangsu, Peoples R China
[2] Nanjing Univ, Affiliated Hosp, Nanjing Drum Tower Hosp, Med Sch, Nanjing, Jiangsu, Peoples R China
[3] Nanjing Univ, Inst Viruses & Infect Dis, Nanjing, Jiangsu, Peoples R China
[4] Huaian 4 Peoples Hosp, Dept Infect Dis, Huaian, Jiangsu, Peoples R China
[5] Huaian 4 Peoples Hosp, Dept Clin Lab, Huaian, Jiangsu, Peoples R China
关键词
Chronic hepatitis B; Nomogram; HBeAg; Seroclearance; Seroconversion; E-ANTIGEN SEROCONVERSION; CLINICAL-PRACTICE GUIDELINES; SIMPLE NONINVASIVE INDEX; CORE ANTIBODY LEVEL; SIGNIFICANT FIBROSIS; TREATMENT RESPONSE; INTERFERON-ALPHA; NATURAL-HISTORY; NAIVE PATIENTS; LAMIVUDINE;
D O I
10.1016/j.aohep.2023.101151
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Introduction and Objectives: Seroclearance of hepatitis B e antigen (HBeAg) is an important treatment goal for patients with chronic hepatitis B (CHB). This study developed a nomogram for predicting HBeAg seroclearance in CHB patients treated with nucleos(t)ide analogues (NAs).Patients and Methods: Five hundred and sixty-nine CHB patients treated with NAs from two institutions between July 2016 to November 2021 were retrospectively included. One institution served as the training set (n = 374) and the other as the external validation set (n = 195). A predictive nomogram was established based on cox regression analysis.Results: The overall HBeAg seroclearance rates were 27.3 and 21.5 % after the median follow-up of 100.2 weeks and 65.1 weeks in the training set and validation set, respectively. In the training set, baseline aspartate aminotransferase, gamma-glutamyl transpeptidase, HBeAg, and hepatitis B core antibody levels were independently associated with HBeAg seroclearance and were used to establish the HBEAg SeroClearance (ESC)-nomogram. The calibration curve revealed that the ESC-nomogram had a good agreement with actual observation. The ESC-nomogram showed relatively high accuracy for predicting 48 weeks, 96 weeks, and 144 weeks of HBeAg seroclearance in the training set (AUCs: 0.782, 0.734 and 0.671) and validation set (AUCs: 0.699, 0.718 and 0.689). The patients with high ESC-nomogram scores (>= 79.51) had significantly higher cumulative incidence of HBeAg seroclearance and seroconversion than patients with low scores (< 79.51) in both sets (P < 0.01).Conclusions: The novel ESC-nomogram showed good performance for predicting antiviral efficacy in HBeAgpositive CHB patients with NAs treatment.(c) 2023 Fundacion Clinica Medica Sur, A.C. Published by Elsevier Espana, S.L.U. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
引用
收藏
页数:8
相关论文
共 50 条
  • [41] A COMPARATIVE ANALYSIS OF THE HBV RNA AND QUANTITATIVE HBSAG KINETICS BETWEEN HBEAG(+) AND HBEAG(-) PATIENTS WITH CHRONIC HEPATITIS B ON PROLONGED NUCLEOS(T)IDE ANALOGUES (NA).
    Shah, Pir A.
    Ishtiaq, Rizwan
    Kaur, Satinder P.
    Gersch, Jeffrey
    Choudhry, Saad
    Kuhns, Mary
    Cloherty, Gavin A.
    Lau, Daryl
    [J]. GASTROENTEROLOGY, 2020, 158 (06) : S1315 - S1315
  • [42] THE EFFICACY AND SAFETY OF PEGINTERFERONA-2A AND NUCLEOS(T)IDE ANALOGUES TREATMENTS IN HBEAG POSITIVE CHRONIC HEPATITIS B WITH ACUTE EXACERBATION
    Lin, Su
    Ye, Q.
    Wang, M.
    Weng, Z.
    Jiang, J.
    Zhu, Y.
    [J]. JOURNAL OF HEPATOLOGY, 2016, 64 : S606 - S606
  • [43] HBeAg-negative chronic hepatitis B: why do I treat my patients with nucleos(t)ide analogues?
    Vigano, Mauro
    Mangia, Giampaolo
    Lampertico, Pietro
    [J]. LIVER INTERNATIONAL, 2014, 34 : 120 - 126
  • [44] On-treatment HBV DNA level could predict HBeAg seroclearance in patients with HBeAg-positive chronic hepatitis B with entecavir therapy
    Huang, Yi-Jie
    Chang, Chi-Sen
    Peng, Yen-Chun
    Yeh, Hong-Zen
    Yang, Sheng-Shun
    [J]. JOURNAL OF THE CHINESE MEDICAL ASSOCIATION, 2017, 80 (06) : 341 - 346
  • [45] HBeAg-negative chronic hepatitis B: why do I treat my patients with nucleos(t)ide analogues
    Lampertico, Pietro
    Colombo, Massimo
    [J]. LIVER INTERNATIONAL, 2009, 29 : 130 - 132
  • [46] Nucleos(t)ide analogue therapy decreases the HBeAg loss rate in HBeAg positive chronic hepatitis B patients with hepatitis flare: a propensity score matching study
    Peng, Chien-Wei
    Jeng, Rachel Wen-Juei
    Chen, Yi-Cheng
    Chien, Rong-Nan
    Liaw, Yun-Fan
    [J]. JOURNAL OF HEPATOLOGY, 2020, 73 : S862 - S863
  • [47] Impact of liver fibrosis in development of hepatocellular carcinoma in HBeAg negative genotype D patients with chronic hepatitis B treated with nucleos(t)ide analogues
    Pellicellii, Adrian M.
    Vignally, Pascal
    Mazzoni, Ettore
    Izzi, Antonio
    Mecenate, Fabrizio
    Romano, Mario
    Barlattani, Angelo
    Villani, Roberto
    Guarascio, Paolo
    Furlan, Caterina
    Cerasari, Giuseppe
    Bacca, Donato
    D'Ambrosio, Cecilia
    Fondacaro, Lucia
    Miglioresi, Lucia
    Bonaventura, Maria Elena
    Andreoli, Arnaldo
    Barbarini, Giorgio
    [J]. HEPATOLOGY, 2012, 56 : 200A - 201A
  • [48] Effectiveness of Response-Guided Peginterferon Alfa-2a Therapy in Nucleos(t)Ide Analogues Treated Patients with Hbeag-Positive Chronic Hepatitis B: Interim Analysis of a Prospective, Multicenter, Randomized Study
    Xie, Qing
    Cai, Wei
    Ouyang, Lijuan
    Gao, Yueqiu
    Li, Shibo
    Xu, Jie
    Zhu, Chuanwu
    Xian, Jianchun
    Zou, Guizhou
    Zhu, Yue-Yong, Sr.
    Huang, Guancheng
    [J]. HEPATOLOGY, 2018, 68 : 232A - 233A
  • [49] Frequency of HBeAg loss and long-term antiviral suppression under nucleos(t)ide treatment in HBeAg positive chronic hepatitis B
    van Bömmel, F
    Mauss, S
    Wünsche, T
    Schürmann, D
    Wiedenmann, B
    Bergk, A
    Weich, V
    Berg, I
    [J]. JOURNAL OF HEPATOLOGY, 2005, 42 : 193 - 193
  • [50] Baseline serum miR-125b levels predict virologic response to nucleos(t)ide analogue treatment in patients with HBeAg-positive chronic hepatitis B
    Zhou, Pu
    Dong, Minhui
    Wang, Jinyu
    Li, Fahong
    Zhang, Jiming
    Gu, Jingwen
    [J]. EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2018, 16 (05) : 3805 - 3812